|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Cancer-Related Problem/Condition | |||||
| Fatigue | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Brain Neoplasms | |||||
| Central Nervous System Neoplasms | |||||
| Nervous System Neoplasms | |||||
| 3 | More general conditions related to this trial | ||||
| Brain Diseases | |||||
| Central Nervous System Diseases | |||||
| Neoplasms | |||||
| Neoplasms by Site | |||||
| Nervous System Diseases | |||||
| Signs and Symptoms | |||||
| 4 | Interventions listed in this trial | ||||
| methylphenidate hydrochloride | |||||
| quality-of-life assessment | |||||
| radiation therapy | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Methylphenidate | |||||
| 6 | More general drug interventions related to this trial | ||||
| Central Nervous System Agents | |||||
| Central Nervous System Stimulants | |||||
| Dopamine Agents | |||||
| Dopamine Uptake Inhibitors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Neurotransmitter Agents | |||||
| Neurotransmitter Uptake Inhibitors | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| Wake Forest University | |||||
| National Cancer Institute (NCI) | |||||